Descrizione Clinica
Cardiovascular system Hemovasal cream 30g 1%
HEMOVASAL 1% CREMA
active ingredients
100 grams of cream contain: active ingredient: eparansolfato salt sodium 1 g Excipients with known effects: p-hydroxybenzoate methyl (E218), p-hydroxybenzoate propile (E216), cetilstearilic alcohol. For the full list of excipients, see paragraph 6.1.Excellent
Monostearate glyceryl, decilestere oleic acid, cetilstearilic alcohol, polyglycolic ether of fatty alcohol, p-hydroxybenzoate methyl (E218), p-hydroxybenzoate propile (E216), blackberry essence, purified waterTherapeutic indications
Treatment of symptoms attributable to venous failure. States of capillary fragility. Minor traumatology. Ematoms. HEMOVASAL is indicated in adults.Contraindications
Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1. HEMOVASAL 1% CREMA should not be applied on open skin lesions, mucous membranes, as well as on locations of infections in case of suppurative processes.Population
Population 2-3 applications per day. Method of administration Each application must be made to cover the entire area affected by the pathology. Pediatric population There are no available data.Conservation
This medicine does not require any special condition of conservation.Warnings
The use, especially if prolonged use of topical products, can give rise to awareness-raising phenomena. In this case, it is necessary to stop treatment and take appropriate therapeutic measures. HEMOVASAL 1% CREMA contains p-hydroxybenzoates that can cause allergic reactions (also delayed). It also contains cetilsterial alcohol that can cause local skin reactions (e.g. contact dermatitis). Do not administer in pediatric age.Interactions
There are no known interactions with other drugs. Interaction studies were carried out only in adults.Effects
An orthoid reaction case was reported probably related to the drug and promptly regreditated with the suspension of therapy. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare professionals are required to report any suspected adverse reaction via the website http://agenziafarmaco.gov.it/it/responsabiliOverdosing
No overdose cases have been reported.Reproductive toxicology studies have excluded any effect of Hemovasal 1% cream on gametogenesis, on embryogenesis and the peri- and post-natal development of the fetus. The caution however recommends to administer Hemovasal 1% cream during pregnancy only in cases of actual need and under the direct control of the doctor.
Source: Farmadati
